About Us
Precision. Progress. Possibility.
CPDC is a not-for-profit advancing nuclear medicine in Canada and beyond through strategic investments, expert guidance and innovative radiopharmaceutical development to benefit patients globally.
CPDC was founded by Dr. John Valliant of McMaster University in 2008 as a Centre of Excellence for Commercialization and Research (CECR) through the NCE, specializing in radiopharmaceutical research and development.
CPDC has been integral to the growth of the radiopharmaceutical ecosystem in Canada.
CPDC successfully incubated and spun-out Fusion Pharmaceuticals Inc., and AtomVie Global Radiopharma and co-founded ARTMS and CanProbe.
Over the last 15 years, CPDC has supported and conducted over 60 clinical trials, including Phase 3, in Canada, North America and Europe.
CPDC and its partners have provided more than 65,000 clinical doses to patients in Canada for a variety of diseases.
We are radiopharmaceutical specialists